NasdaqGS:UTHRBiotechs
Is It Time To Reassess United Therapeutics (UTHR) After Recent Pulmonary Hypertension Headlines?
If you are wondering whether United Therapeutics at around US$476 per share still offers value, you are not alone. This article is built to help you weigh what that price actually represents.
The stock has been flat over the last 7 days, up 2.4% over 30 days, with a year to date return of 4.2% decline and a 1 year return of 25.0%, extending to 95.3% over 3 years and 174.1% over 5 years.
Recent headlines around United Therapeutics have focused on its position in treatments for pulmonary...